Selinexor for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Anum, Babar [1 ]
Hina, Zubair [2 ]
Mainoma, Bano [3 ]
Sana, Rafique [4 ]
Arzu, Shahid [1 ]
Maham, Babar
Waleed, Madeeha S. [5 ]
Arslan, Inayat [6 ]
Danish, Safi [7 ]
机构：
[1] Khyber Girls Med Coll, Karachi, Pakistan
[2] Rawalpindi Med Univ, Rawalpindi, Pakistan
[3] Deccan Coll Med Sci, Hyderabad, India
[4] Liaquat Natl Med Coll, Karachi, Pakistan
[5] Lower Bucks Hosp, Bristol, PA USA
[6] HSHS St Mary Hosp, Decatur, IL USA
[7] JW Ruby Mem Hosp, Morgantown, WV USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2022年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-046
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [1] Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
    Chen, Christine I.
    Bahlis, Nizar J.
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    LeBlanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie S.
    Rossi, Adriana C.
    Sheehan, Heidi
    Van Domelen, Dane
    Kazuharu, Kai
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    [J]. BLOOD, 2020, 136
  • [2] Selinexor for the treatment of patients with relapsed or refractory multiple myeloma
    Babar, Anum
    Babar, Maham
    Zubair, Hina
    Shahid, Arzu
    Rafique, Sana
    Bano, Maimona
    Waleed, Madeeha Subhan
    Khan, Maimoona
    Inayat, Arslan
    Safi, Danish
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (03) : 535 - 546
  • [3] A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bassali, J.
    Gould, I
    Mladsi, D. D.
    Kaye, J. A.
    Shah, J.
    Mehta, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S33 - S33
  • [4] A US Budget Impact Model for Selinexor in Combination with Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Gould, Ian
    Bassali, Jan
    Mehta, Jyotsna
    Shah, Jatin
    Mladsi, Dee Dee
    [J]. BLOOD, 2019, 134
  • [5] Selinexor in relapsed/refractory multiple myeloma
    Richter, Joshua
    Madduri, Deepu
    Richard, Shambavi
    Chari, Ajai
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [6] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    White, Darrell
    LeBlanc, Richard
    Venner, Chritopher
    Bahlis, Nizar J.
    Lentzsch, Suzanne
    Gasparetto, Cristina J.
    Chen, Christine
    Lipe, Brea
    Sutherland, Heather
    Tuchman, Sascha
    Baljevic, Muhamed
    Kotb, Rami
    Sebag, Michael
    Callander, Nancy
    Bensinger, William
    Kai, Kazuharu
    Liu, Jianjun
    Sheehan, Heidi
    Estepan, Daniel Nova
    Shah, Jatin
    Schiller, Gary J.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E55 - E55
  • [7] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [8] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    [J]. BLOOD, 2017, 130
  • [9] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    [J]. VALUE IN HEALTH, 2019, 22 : S497 - S498
  • [10] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    [J]. EJHAEM, 2021, 2 (01): : 56 - 65
12345